Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBT (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed EBT for 15 consecutive years, with $239.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 47.23% year-over-year to $239.4 million, compared with a TTM value of $705.4 million through Dec 2025, up 45.14%, and an annual FY2025 reading of $705.4 million, up 45.14% over the prior year.
  • EBT was $239.4 million for Q4 2025 at Neurocrine Biosciences, down from $291.8 million in the prior quarter.
  • Across five years, EBT topped out at $291.8 million in Q3 2025 and bottomed at -$103.3 million in Q1 2023.
  • Average EBT over 4 years is $109.2 million, with a median of $115.6 million recorded in 2023.
  • The sharpest move saw EBT surged 153.42% in 2021, then crashed 57.39% in 2025.
  • Year by year, EBT stood at $30.5 million in 2021, then skyrocketed by 549.84% to $198.2 million in 2023, then decreased by 17.96% to $162.6 million in 2024, then soared by 47.23% to $239.4 million in 2025.
  • Business Quant data shows EBT for NBIX at $239.4 million in Q4 2025, $291.8 million in Q3 2025, and $159.5 million in Q2 2025.